Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 2/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616944 | 0.84 | MAPK14 (0.51) | MAPK14RAF1BRAFEPHB2HPGD | |
| SCHEMBL2084851 | 0.81 | MAPK14 (0.47) | GRNSORT1MAPK14RAF1BRAF | |
| SCHEMBL2928086 | 0.80 | ALDH1A1 (0.46) | GRNSORT1HPGDNTRK1ALDH1A1 | |
| SCHEMBL15519630 | 0.79 | GRN (0.50) | GRNSORT1MAPK14RAF1BRAF | |
| SCHEMBL15516042 | 0.79 | GRN (0.49) | GRNSORT1MAPK14RAF1BRAF | |
| SCHEMBL15517497 | 0.76 | GRN (0.46) | GRNSORT1MAPK14KLKB1SCN9A | |
| SCHEMBL16749217 | 0.76 | GRN (0.53) | GRNSORT1MAPK14KLKB1DDR2 | |
| SCHEMBL15517667 | 0.75 | GRN (0.46) | GRNSORT1MAPK14KLKB1SCN9A | |
| SCHEMBL12705321 | 0.74 | GRN (0.68) | GRNSORT1HPGDNTRK1ALDH1A1 | |
| SCHEMBL4434009 | 0.74 | GRN (0.51) | GRNSORT1MAPK14SCN9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | GRN 3968/4885SORT1 3228/4885MAPK14 128/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | GRN 3157/4885SORT1 4054/4885MAPK14 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.